Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients
Authors:
- GötZ ThomallaGTGötZ Thomalla
- Christian SchwarkCSChristian Schwark
- Jan SobeskyJSJan Sobesky
- Erich BluhmkiEBErich Bluhmki
- Jochen B. FiebachJFJochen B. Fiebach
- Jens FiehlerJFJens Fiehler
- Olivier Zaro WeberOWOlivier Zaro Weber
- Thomas KucinskiTKThomas Kucinski
- Eric JuettlerEJEric Juettler
- Peter A. RinglebPRPeter A. Ringleb
- Hermann ZeumerHZHermann Zeumer
- Cornelius WeillerCWCornelius Weiller
- 1 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 37 (3) , 852-858
Abstract
Background and Purpose— We compared outcome and symptomatic bleeding complications of intravenous tissue plasminogen activator (IV-tPA) within 6 hours of symptom onset in MRI-selected patients with acute middle cerebral artery infarction with the pooled data of the large stroke tPA trials. Methods— Patients were examined by perfusion-weighted and diffusion-weighted imaging ≤6 hours. Within 3 hours, patients were treated according to Second European-Australasian Acute Stroke Study (ECASS II) criteria. After 3 to 6 hours, treatment with IV-tPA was performed based on MRI findings. Favorable outcome was assessed after 90 days using a dichotomized modified Rankin scale score of 0 to 1. Intracerebral bleeding complications were assessed on follow-up MRI or computed tomography. Data were compared with the pooled placebo and pooled tPA patients of the ATLANTIS, ECASS, and National Institute of Neurological Disorders and Stroke (NINDS) tPA trials. Results— From 174 MRI-selected tPA patients, 62% (n=108) were treated in ≤3 hours and 38% (n=66) after 3 to 6 hours. Favorable outcome was more frequent in MRI-selected tPA patients (48% [95% CI, 39 to 54]) compared with pooled placebo (33% [95% CI, 31 to 36]; P P =0.046). Odds ratios for favorable outcome in the MRI-selected tPA group were 1.82 (1.32 to 2.51) compared with the pooled placebo and 1.39 (1.01 to 1.92) compared with the pooled tPA group. The rate of symptomatic intracerebral hemorrhage in MRI-selected tPA patients (3% [95% CI, 0 to 5]) was lower than in the pooled tPA group (8% [95% CI, 7 to 10]; P =0.012) and comparable to the pooled placebo group (2% [95% CI, 1 to 3]; P =0.392). Conclusions— This study supports that it is safe and effective to expand the time window for IV-tPA up to 6 hours in patients with tissue at risk as defined by MRI.Keywords
This publication has 22 references indexed in Scilit:
- Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection ProtocolStroke, 2005
- Magnetic Resonance Imaging Criteria for Thrombolysis in Acute Cerebral InfarctStroke, 2005
- The Desmoteplase in Acute Ischemic Stroke Trial (DIAS)Stroke, 2005
- Which Time-to-Peak Threshold Best Identifies Penumbral Flow?Stroke, 2004
- Probability of Cortical Infarction Predicted by Flumazenil Binding and Diffusion-Weighted Imaging Signal IntensityStroke, 2004
- Beyond MismatchStroke, 2003
- Baseline Magnetic Resonance Imaging Parameters and Stroke Outcome in Patients Treated by Intravenous Tissue Plasminogen ActivatorStroke, 2003
- Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 HoursStroke, 2002
- CT and Diffusion-Weighted MR Imaging in Randomized OrderStroke, 2002
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995